Abstract Details

Title Predictors and Outcomes of Stress Cardiomyopathy in Aneurysmal Subarachnoid Hemorrhage

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) S31 - Stroke Risk Factors, Outcomes, and Prevention (3:54 PM-4:06 PM)

Poster/Presentation
Number 003

Objective This study aims to identify the risk factors and clinical outcomes, including discharge disability and hospital length of stay (LOS), of stress cardiomyopathy (SCM) after aneurysmal subarachnoid hemorrhage (aSAH).

Background Neurogenic stress following aSAH can precipitate SCM, a reversible cardiac syndrome. In the modern era of aSAH care, marked by significant advancements in neuroendovascular treatment for aneurysms, the predictors and impact of SCM on clinical outcomes remain unclear.

Design/Methods This single-center retrospective study included consecutive aSAH patients (August 2003 – March 2024). Variables with significant differences in univariable tests between patients with and without SCM, diagnosed using modified Mayo Clinic criteria, were entered into a multivariable logistic regression model to identify predictors of SCM. Multivariable models adjusted for age, sex, Hunt & Hess (HH) scores, baseline modified Rankin Scale (mRS) scores, and vasospasm were used to study the associations between SCM and poor discharge disability (mRS ≥ 3) and LOS.

Results

Among 374 aSAH patients (mean age 56±14 years, 67% female), 209 (56%) underwent TTE, of which, 15 (7%) were diagnosed with SCM. In the multivariable analysis, female sex (aOR 13.20, 95% CI [1.55–112.43]), vasospasm (aOR 6.98, 95% CI [1.43–33.87], and HH scores (aOR 2.04, 95% CI [1.10–3.80]) were significantly associated with SCM, despite adjustment for acute CSF diversion therapy and admission glucose values.

174 (47%) patients had poor discharge disability, and the mean LOS was 20±12 days. However, SCM was not independently associated with poor discharge disability (aOR 2.15. 95% CI [0.40–11.49]) or longer LOS (β = 3.209, p = 0.53).

Conclusions In this contemporary aSAH cohort, female sex, vasospasm, and higher HH scores were significant predictors of SCM development. Although SCM did not impact clinical outcomes, future prospective studies employing a standardized approach to SCM evaluation are needed to fully elucidate its impact on clinical outcomes.

Authors/Disclosures
Eileen Yung, MD PRESENTER	Dr. Yung has nothing to disclose.
Jeet Metu, Student	Mr. Metu has nothing to disclose.
James Devanney, DO	Dr. Devanney has nothing to disclose.
Omar Alwakaa, MD	Dr. Alwakaa has nothing to disclose.
Jean Filo, MD	Dr. Filo has nothing to disclose.
Thomas B. Fodor, MD	Dr. Fodor has nothing to disclose.
Christopher Lau, MD	Dr. Lau has nothing to disclose.
Robert W. Regenhardt, MD, PhD	Dr. Regenhardt has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genomadix. Dr. Regenhardt has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Rapid Medical. Dr. Regenhardt has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Johnson and Bell Trial Lawyers. Dr. Regenhardt has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Buckley, Theroux, Kline, & Cooley Trial Lawyers. The institution of Dr. Regenhardt has received research support from National Institutes of Health. The institution of Dr. Regenhardt has received research support from Society of Vascular and Interventional Neurology. The institution of Dr. Regenhardt has received research support from Heitman Foundation.
Bruno A. Benitez, MD	Dr. Benitez has nothing to disclose.
Corey R. Fehnel, MD, FAAN (Beth Israel Deaconess Medical Center)	Dr. Fehnel has received personal compensation in the range of $500-$4,999 for serving as a Consultant for XRHealth. The institution of Dr. Fehnel has received research support from National Institute on Aging .
Jason Yoon, MD (Beth Israel Deaconess Medical Center)	Dr. Yoon has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Aquifer.
Magdy H. Selim, MD, PhD (Beth Israel Deaconess Med. Ctr.)	Dr. Selim has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alnylam. The institution of Dr. Selim has received research support from NIH/NINDS. Dr. Selim has received publishing royalties from a publication relating to health care.
Philipp Taussky, MD	Dr. Taussky has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Medtronic. Dr. Taussky has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Cerenovus. Dr. Taussky has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Frontiers.
Justin Granstein, MD (Beth Israel Deaconss Medical Center, Harvard Medical School)	Dr. Granstein has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Cerenovus.
Christopher S. Oglivy, MD	Dr. Oglivy has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for medtronic.
Alvin Das, MD	Dr. Das has nothing to disclose.

��ɫ��

��ɫ��